The global balloon catheter market is witnessing steady growth, driven by the rising prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, and advancements in catheter technologies. Balloon catheters are widely used in procedures such as angioplasty, stent placement, and valvuloplasty, offering improved patient outcomes with shorter recovery times. The market is further bolstered by the growing aging population, which is more susceptible to heart-related conditions, and the expanding adoption of interventional cardiology techniques in both developed and emerging markets. Technological innovations, including drug-coated and bioresorbable balloon catheters, are enhancing the efficacy and safety of these devices, contributing to market growth.
Global Balloon Catheter Market size was valued at USD 4.54 billion in 2024 and is projected to reach USD 7.30 billion by 2032, with a CAGR of 6.10% during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-balloon-catheter-market
Below are the Top Balloon Catheter Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Boston Scientific Corporation
|
Boston Scientific Corporation is a global leader in medical devices, particularly in the interventional cardiology segment, offering a diverse portfolio of balloon catheters. Boston Scientific is known for its commitment to innovation, regularly introducing new technologies to enhance procedural outcomes and patient care. Its strong global distribution network and partnerships with healthcare providers make it a dominant force in the balloon catheter market, with a focus on expanding access to minimally invasive cardiovascular treatments worldwide.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2023, Boston Scientific participated in Stifel's 2023 Healthcare Conference. Dan Brennan, EVP and CFO, and Lauren Tengler, VP of Investor Relations, engaged in a 30-minute Q&A session at 8:00 a.m. ET. A live webcast and replay were available on their Investor Relations website.
|
|
2.
|
Medtronic
|
Medtronic is a leading global healthcare solutions company, offering a wide range of innovative medical devices, including advanced balloon catheter technologies. The company’s balloon catheters are integral to its cardiovascular portfolio, particularly in treating coronary artery disease and peripheral vascular conditions. The company emphasizes research and development, driving continuous improvements in balloon catheter technology, including drug-coated and bioresorbable designs. With a robust global distribution network and a strong presence in both developed and emerging markets, Medtronic remains a key player in the balloon catheter market, committed to advancing minimally invasive cardiovascular treatments.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2022, Medtronic received FDA approval for its Freezor and Freezor Xtra catheters to treat pediatric atrioventricular nodal reentrant tachycardia (AVRNT). This cryoablation therapy, is effective for over 140,000 patients worldwide, targets abnormal heart rhythms in children, helping to prevent life-threatening complications and support normal heart function.
|
|
3.
|
Abbott
|
Abbott is a global healthcare company renowned for its advanced medical device offerings, including a comprehensive range of balloon catheters for cardiovascular interventions. The company focuses on integrating cutting-edge technologies to enhance the safety, precision, and effectiveness of balloon catheter procedures. Abbott’s global reach, combined with its emphasis on research and development, positions it as a key player in the balloon catheter market, contributing to the advancement of minimally invasive treatments for cardiovascular diseases.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In 2024, Abbott entered into global partnership with Medtronic on August 7, 2024, Abbott's advanced FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed.
|
|
4.
|
Terumo Medical corporation
|
Terumo Medical Corporation is a prominent player in the global medical device industry, with a specialized focus on cardiovascular solutions, including balloon catheters. Terumo’s innovations emphasize precision, ease of use, and enhanced patient safety, making their balloon catheters highly sought after for complex procedures. With a strong commitment to research and technological advancement, Terumo continuously improves its catheter designs to meet the evolving needs of interventional cardiology.
|
• FINECROSS M3 Coronary Micro-Guide Catheter
• FINECROSS MG Coronary Micro-Guide Catheter
• GLIDECATH Hydrophilic Coated Catheter
• HEARTRAIL III Guiding Catheter
• NAVICROSS Support Catheter
• OPTITORQUE Coronary Diagnostic Catheter
• PRIORITYONE Aspiration Catheter
• PROGREAT Microcatheters
• PROGREAT ALPHA Peripheral Microcatheter
• PG Pro Peripheral Microcatheter
• METACROSS RX (0.035") PTA Balloon Dilatation Catheter
• METACROSS OTW (0.035") PTA Balloon Dilatation Catheter
• CROSSTELLA RX (0.018") PTA Balloon Dilatation Catheter
• CROSSTELLA OTW (0.018") PTA Balloon Dilatation Catheter
• CROSSTELLA OTW (0.018") PTA Balloon Dilatation Catheter
• CROSPERIO RX (0.014") PTA Balloon Dilatation Catheter
• CROSPERIO OTW PTA Balloon Dilatation Catheter
• TAKERU PTCA Balloon Dilatation Catheter
• FINECROSS M3 Coronary Micro-Guide Catheter
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In 2022, MicroVention announced the first enrollment in the STRAIT study for the BOBBY Balloon Guide Catheter, designed for endovascular acute ischemic stroke treatment. The BOBBY catheter, used successfully in a severe stroke case, improves balloon preparation, navigability, and compatibility with the SOFIA Plus 6Fr Aspiration Catheter.
|
|
5.
|
BD
|
BD is a global medical technology company specializing in a wide range of medical devices, including balloon catheters for vascular and interventional procedures. The company’s balloon catheter portfolio includes products designed for both coronary and peripheral applications, emphasizing ease of use, safety, and effective patient outcomes. The company’s global presence, combined with a focus on innovation and quality, makes BD a significant player in the balloon catheter market, addressing the growing demand for minimally invasive cardiovascular treatments worldwide.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2024, BD (Becton, Dickinson and Company) was named one of Fortune's Most Innovative Companies in 2024. The recognition highlighted BD’s commitment to product and process innovation, as well as its culture of fostering creativity. On March 03, 2024 accolade reflected the company's dedication to advancing health care through continuous improvement and customer collaboration.
|
Conclusion
The global balloon catheter market is poised for sustained growth, fueled by the increasing prevalence of cardiovascular diseases, the rising demand for minimally invasive procedures, and continuous technological advancements. While North America maintains market dominance due to its advanced healthcare infrastructure and high incidence of heart-related conditions, the Asia Pacific region is emerging as a significant growth area, driven by rising healthcare investments and awareness. Innovations such as drug-coated and bioresorbable balloon catheters are enhancing treatment efficacy, further propelling market expansion.
